Figure 8.

The bispecific C-7 VHH triggers CD16⁺ NK92 cells to control tumor growth using patient metastatic CRC cells. Dissociated CRC peritoneal metastatic samples ± NK92 CD16⁺ ±100 nM C-7 were cultured for 1, 3, and 7 days at multiple E:T ratios, i.e., 1:1 n = 6, 1:5 n = 5, 1:10 n = 5. The significance levels refer to the conditions: “T+NK92 CD16⁺” versus “T+NK92 CD16⁺+C-7”. Data are presented as mean ± SEM. Significance is presented as p < 0.05 *, <0.01 **. p-values were determined by two-way ANOVA with Dunnett’s multiple comparison analysis. Abbreviations: T = tumor, C-7 = C21-7D12 bispecific VHH.